Targeted Therapy for Mesothelioma: 2026 Guide
Targeted therapy options for mesothelioma including BAP1, NF2, and TEAD inhibitors. Current clinical trials and who may benefit.
What Is Targeted Therapy?
Targeted therapy uses drugs designed to attack specific genetic abnormalities in cancer cells. Unlike chemotherapy, which kills rapidly dividing cells indiscriminately, targeted therapies aim for precise molecular targets found primarily in tumor cells.
For mesothelioma, researchers have identified several genetic mutations that drive tumor growth. By developing drugs that interfere with these specific pathways, oncologists hope to achieve better outcomes with fewer side effects than traditional chemotherapy.
Targeted therapy is part of precision medicine, which tailors treatment based on the genetic profile of each patient’s tumor. Genetic testing helps identify which targeted therapies may be most effective.
Key Genetic Targets in Mesothelioma
BAP1 Mutations
BAP1 (BRCA1-associated protein 1) is the most commonly mutated gene in mesothelioma, affecting approximately 60% of cases. BAP1 normally functions as a tumor suppressor, helping cells repair DNA damage. When BAP1 is lost:
- Cells cannot properly repair DNA damage
- Tumor growth is accelerated
- The cancer may become more aggressive
Researchers are testing drugs that exploit BAP1-deficient cells’ vulnerability, including EZH2 inhibitors such as tazemetostat, PARP inhibitors, and histone deacetylase (HDAC) inhibitors. A multicenter phase 2 trial (NCT02860286) tested tazemetostat in BAP1-deficient mesothelioma.
NF2 Mutations
NF2 (neurofibromin 2) mutations occur in approximately 40% of mesotheliomas. NF2 regulates the Hippo signaling pathway, which controls cell growth. When NF2 is mutated, the Hippo pathway becomes dysregulated, TEAD transcription factors become overactive, and cells proliferate uncontrollably. TEAD inhibitors are designed to block this downstream effect of NF2 loss.
CDKN2A Deletions
CDKN2A is deleted in up to 70% of mesotheliomas. This gene produces proteins (p16 and p14ARF) that normally prevent uncontrolled cell division. CDK4/6 inhibitors like palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) may help restore cell cycle control in tumors with CDKN2A loss, and are being evaluated in mesothelioma-specific trials.
TEAD Inhibitors: Promising New Approach
TEAD inhibitors represent one of the most promising targeted therapy developments for mesothelioma. These drugs target transcriptional enhanced associate domain (TEAD) proteins that become overactive when the Hippo pathway is disrupted.
VT3989 Trial
Vivace Therapeutics is testing VT3989, a pan-TEAD inhibitor, in an open-label Phase 1/2 trial (NCT04665206):
- Targeting NF2-mutated cancers including mesothelioma
- Studied alone and in combination, with combination cohorts actively recruiting
- Early data point to disease control in NF2-altered tumors
ODM-212 (TEADES Trial)
Orion Pharma initiated the Phase 2 TEADES trial in December 2025:
- Testing oral pan-TEAD inhibitor ODM-212
- Enrolling approximately 300 patients globally
- Targets Hippo pathway dysfunction
EZH2 Inhibitors for BAP1-Deficient Tumors
EZH2 is an enzyme that can drive cancer growth in BAP1-deficient tumors. By blocking EZH2, researchers hope to restore normal cell function.
Tazemetostat (Tazverik)
Tazemetostat is FDA-approved for certain sarcomas and is being studied in mesothelioma:
- Targets BAP1-deficient tumors
- Phase 2 trials ongoing
- May be combined with immunotherapy
If you have BAP1-deficient mesothelioma, ask your oncologist about EZH2 inhibitor trials. Genetic testing can confirm BAP1 status.
ADI-PEG20: Arginine Depletion Therapy
ADI-PEG20 (pegargiminase) works differently from traditional targeted therapies. Many mesothelioma cells lack the ability to produce arginine, an essential amino acid. ADI-PEG20 depletes arginine in the bloodstream, effectively starving these cancer cells.
ATOMIC-Meso Trial Results
The Phase 3 ATOMIC-Meso trial showed remarkable results:
| Outcome | ADI-PEG20 + Chemo | Chemo Alone |
|---|---|---|
| 3-year survival | 4x higher | Baseline |
| Progression-free survival | 6 months | 4.1 months |
| Overall survival improvement | +2 months | , |
Based on ATOMIC-Meso results, ADI-PEG20 may be under FDA review. This could represent the first targeted therapy specifically approved for mesothelioma.
Who May Benefit from Targeted Therapy?
Targeted therapy works best when doctors can identify a specific target in your tumor. Consider targeted therapy if:
You have a confirmed genetic mutation:
- BAP1 loss (60% of cases)
- NF2 mutation (40% of cases)
- CDKN2A deletion (70% of cases)
Standard treatments have stopped working:
- After chemotherapy progression
- After immunotherapy progression
- As part of clinical trial enrollment
You’re a candidate for clinical trials:
- Adequate performance status
- No contraindications
- Tumor tissue available for genetic testing
Genetic Testing for Targeted Therapy
To determine if targeted therapy may help, genetic testing of your tumor is essential.
What Tests Are Available
| Test Type | What It Shows | Turnaround |
|---|---|---|
| Next-generation sequencing (NGS) | Full genetic profile | 2-3 weeks |
| Fluorescence in situ hybridization (FISH) | Specific deletions (CDKN2A) | 3-5 days |
| Immunohistochemistry (IHC) | Protein expression (BAP1) | 2-3 days |
Where to Get Tested
- Major cancer centers offer comprehensive testing
- Commercial labs (Foundation Medicine, Tempus, Caris)
- Academic medical centers with mesothelioma programs
Current Clinical Trials (2026)
Several clinical trials are testing targeted therapies for mesothelioma:
Phase 1/2 Trials
Vivace Therapeutics’ VT3989 (NCT04665206), a pan-TEAD inhibitor, is recruiting for NF2-mutated solid tumors including mesothelioma, with combination cohorts open at US sites. Tazemetostat combinations with immunotherapy are enrolling people with BAP1-deficient tumors at major cancer centers including Memorial Sloan Kettering and MD Anderson.
How to Find Trials
- ClinicalTrials.gov: Search “mesothelioma targeted therapy”
- Your oncologist can check NCI trial databases
- Major mesothelioma centers maintain current trial lists
- Commercial matching services (EmergingMed, TrialJectory)
Side Effects of Targeted Therapy
Targeted therapies generally cause different side effects than chemotherapy:
Common side effects:
- Fatigue (20-40%)
- Nausea (15-25%)
- Elevated liver enzymes (10-20%)
- Skin rash (varies by drug)
Serious but less common:
- Cardiac effects (some drugs)
- Liver toxicity
- Interstitial lung disease (rare)
Most side effects are manageable and less severe than chemotherapy-related effects like blood count suppression.
Combining Targeted Therapy with Other Treatments
The future of mesothelioma treatment likely involves combining targeted therapy with:
Immunotherapy:
- TEAD inhibitors may enhance immune response
- EZH2 inhibitors being tested with checkpoint inhibitors
- Combination approaches in multiple trials
Chemotherapy:
- ADI-PEG20 approved in combination with chemotherapy
- Sequential approaches being studied
- Targeted therapy may help shrink tumors pre-surgery
- Post-surgery maintenance under investigation
References
Genome Medicine. (2019). BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
https://pubmed.ncbi.nlm.nih.gov/30777124/
ClinicalTrials.gov (NCT04665206). (2025). Study of VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations.
https://clinicaltrials.gov/study/NCT04665206
JAMA Oncology. (2024). Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.
https://pubmed.ncbi.nlm.nih.gov/38358753/
Translational Lung Cancer Research. (2017). Drug development against the Hippo pathway in mesothelioma.
https://pubmed.ncbi.nlm.nih.gov/28713678/
Frontiers in Oncology. (2021). Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.
https://pubmed.ncbi.nlm.nih.gov/34249695/
Reader Q&A
Frequently Asked Questions
Is targeted therapy approved for mesothelioma?
Currently, no targeted therapies are specifically FDA-approved for mesothelioma, though ADI-PEG20 may be under review. Several drugs are available through clinical trials, and some approved for other cancers may be used off-label.
How do I know if I have a targetable mutation?
Genetic testing of your tumor tissue can identify mutations like BAP1, NF2, and CDKN2A. Ask your oncologist about next-generation sequencing (NGS) testing.
Are targeted therapies better than chemotherapy?
For patients with specific mutations, targeted therapies may offer better outcomes with fewer side effects. However, they only work if your tumor has the targeted abnormality. Most patients still receive chemotherapy or immunotherapy as first-line treatment.
Can I receive targeted therapy with immunotherapy?
Yes, clinical trials are testing combinations of targeted therapy with checkpoint inhibitors. Some researchers believe targeting specific pathways may enhance the immune response to cancer.
How do I find targeted therapy clinical trials?
Search ClinicalTrials.gov for “mesothelioma targeted therapy” or ask your oncologist. Major mesothelioma centers maintain current trial lists and can help determine your eligibility.
How close are we to a cure for mesothelioma?
No cure exists for mesothelioma as of 2026. Approved first-line treatments include nivolumab plus ipilimumab immunotherapy (FDA-approved, with 3-year PFS of 14% vs. 1% for chemotherapy) and pembrolizumab plus chemotherapy (ORR 62% vs. 38%). Over 80 active clinical trials test emerging therapies like enzyme therapy (ADI-PEG20 extended survival 4-fold at 3 years), cancer vaccines (UV1 doubled response rates), and targeted therapies, with median survival reaching 18+ months in some multimodal approaches. Research shows improved outcomes but no evidence of curative potential yet.
What is the best hospital for mesothelioma treatment?
University of Texas MD Anderson Cancer Center ranks No. 1 in the U.S. for cancer treatment in 2025, for the fifth consecutive year, and treats more people with mesothelioma than nearly any other center. Other highly ranked hospitals for pleural mesothelioma include Brigham and Women’s Hospital and Massachusetts General Hospital, while Mayo Clinic-Rochester leads for peritoneal mesothelioma. People with mesothelioma receive care at these centers, which offer multidisciplinary teams and access to clinical trials. Rankings from U.S. News & World Report reflect factors like patient outcomes and expertise volume.